Case Reports in Dermatological Medicine

Case Reports in Dermatological Medicine / 2018 / Article

Case Report | Open Access

Volume 2018 |Article ID 4125856 | https://doi.org/10.1155/2018/4125856

Gerhard Eichhoff, Noriko Soffi Harun, "Psoriatic Arthritis and Nail Psoriasis in a Patient with Concomitant Atopic Dermatitis", Case Reports in Dermatological Medicine, vol. 2018, Article ID 4125856, 3 pages, 2018. https://doi.org/10.1155/2018/4125856

Psoriatic Arthritis and Nail Psoriasis in a Patient with Concomitant Atopic Dermatitis

Academic Editor: Ioannis D. Bassukas
Received06 Dec 2017
Revised17 Jan 2018
Accepted23 Jan 2018
Published18 Feb 2018

Abstract

Coincidence of psoriasis and atopic dermatitis (AD) is considered to be very rare, as a result of the different underlying immunopathology. This case report describes a patient with long history of atopy and AD who developed psoriatic nail changes and psoriatic arthritis (PsA). The patient’s skin, however, revealed only eczematous lesions without manifestation of psoriasis.

1. Introduction

Psoriasis and atopic dermatitis (AD) are the most frequent chronic inflammatory skin diseases. Both are estimated to have prevalence of 2–5% in the adult population. These skin diseases are associated with other immune disorders, such as psoriatic arthritis or allergic asthma [1]. Approximately 20% of patients with psoriasis develop psoriatic arthritis (PsA), whereas 5% of patients with PsA have no active skin lesions [2]. PsA is correlated with psoriatic nail changes [3].

While both psoriasis and AD are common skin disorders, concomitant occurrence of these two diseases is rare. This rarity is likely explained by recent immunologic studies that revealed that psoriasis is a more TH1/TH17-driven disease, whereas AD is a predominantly TH2-driven disease [4].

Here, the authors report the case of a patient with PsA in the hands, psoriatic nail changes without accompanying psoriasis of the skin, and concomitant active AD.

2. Case Report

A 33-year-old male patient of European descent was referred to the dermatological outpatient clinic for recurrent paronychia that did not respond to several courses of terbinafine. The patient had a history of atopy with hay fever and AD, which manifested in early childhood. In his early 20s, his AD was treated with a one-year course of cyclosporine. Since then, the eczema was managed with topical steroids. He had no history or family history of psoriasis or PsA.

Over the prior 12 months, he developed painful swelling in his joints in his hands and concomitant nail changes. Since onset of these symptoms, the patient did not notice major changes in the severity of his eczema that occurred with regular most likely stress-related minor flare-ups. The patient presented with oil drops on almost all fingernails and on nails of both big toes together with mild distal onycholysis. Furthermore, swelling with redness of the distal interphalangeal joints (DIP) of the right index and left little finger was evident (Figure 1). These findings were consistent with psoriatic nail changes and PsA. An X-ray of the patient’s hands showed entheseal expansion of the DIP of the right ring finger and left little finger, suggesting PsA. Therefore, PsA was diagnosed as the patient met 4 points of the classification criteria for psoriatic arthritis (CASPAR) [5].

Whole-body examination revealed active AD on the backs of the knees with ill-defined erythematous patches with scaling, lichenification, and excoriations (Figure 2). Besides the nail changes, no psoriatic skin lesions were observed. Laboratory analyses underscored the atopy of the patient with elevated IgE levels (689 IU/mL). Rheumatoid factor was not detectable, and C-reactive protein was in the normal range. Treatment with methotrexate 15 mg once weekly was commenced. The patient was recommended to continue Mometasone Furoate ointment for his AD. At 8 weeks of follow-up, neither the patient’s joint pain and swelling nor nail changes improved markedly. His eczema did, however, slightly improve. It is yet too early to judge the efficacy of methotrexate.

3. Discussion

Concomitant psoriasis and AD are rare. Henseler and Christophers found that AD is 25 times less frequently associated with psoriasis than one would expect based on prevalence of the individual diseases [6]. In 1987, Christophers and Henseler hypothesized that psoriasis and AD were mutually exclusive [7]. In recent years, immunological studies provided support for this hypothesis, attributing this exclusion to the more TH1/TH17-dominated immune response underlying psoriasis and the TH2-dominated immune response found in patients with atopic eczema. Furthermore, independent regulations of these two immune phenotypes have been shown to rarely overlap [4].

On the other hand, AD and psoriasis can share both clinical and immunological features. This especially applies to subtypes of AD, such as AD within Asian populations, paediatric AD, and intrinsic AD, where TH17 does seem to play a key role [8]. The patient reported here, being from European descent and suffering from early-onset extrinsic eczema, does not fit into these subtypes of AD.

The IL-23/IL-17 axis plays a crucial role not only in the pathogenesis in psoriasis but also in PsA [9]. Nail changes are a marker of psoriatic arthritis, and magnetic resonance imaging showed that nail enthesis is associated with the nail, the distal phalanx, and distal interphalangeal joints and therefore may cause PsA [10].

This report provides the first description to date of a patient with AD who developed PsA with nail changes without further skin manifestation of psoriasis. Whereas no other study on concomitant psoriasis and AD described patients with PsA, Hajdarbegovic et al. reported PsA to be significantly less likely to be associated with atopy than isolated skin psoriasis [11].

Treatment of patients with concomitant psoriasis and AD can be complicated by the fact that tumor necrosis factor-alpha (TNF-alpha) inhibitors and ustekinumab, the monoclonal antibody against the p40 subunit of interleukin-12 (IL-12) and IL-23, have been shown to provoke eczema or a flare of AD as a side effect [12]. As a result, systemic treatment with cyclosporine, methotrexate, and/or apremilast is preferable as these treatments can be efficacious for both AD and psoriasis, including PsA [13]. Further research of the involved cytokines including the patient’s individual cytokine profile will be needed to offer these patients more targeted treatment.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

  1. C. E. M. Griffiths, P. van de Kerkhof, and M. Czarnecka-Operacz, “Psoriasis and Atopic Dermatitis,” Dermatology and Therapy, vol. 7, pp. 31–41, 2017. View at: Publisher Site | Google Scholar
  2. K. Reich, K. Krüger, R. Mössner, and M. Augustin, “Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis,” British Journal of Dermatology, vol. 160, no. 5, pp. 1040–1047, 2009. View at: Publisher Site | Google Scholar
  3. P. Sobolewski, I. Walecka, and K. Dopytalska, “Nail involvement in psoriatic arthritis,” Reumatología Clínica, vol. 55, no. 3, pp. 131–135, 2017. View at: Publisher Site | Google Scholar
  4. S. Eyerich, A. T. Onken, S. Weidinger et al., “Mutual antagonism of T cells causing psoriasis and atopic eczema,” The New England Journal of Medicine, vol. 365, no. 3, pp. 231–238, 2011. View at: Publisher Site | Google Scholar
  5. W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease, and H. Mielants, “Classification criteria for psoriatic arthritis: development of new criteria from a large international study,” Arthritis & Rheumatology, vol. 54, no. 8, pp. 2665–2673, 2006. View at: Publisher Site | Google Scholar
  6. T. Henseler and E. Christophers, “Disease concomitance in psoriasis,” Journal of the American Academy of Dermatology, vol. 32, no. 6, pp. 982–986, 1995. View at: Publisher Site | Google Scholar
  7. E. Christophers and T. Henseler, “Contrasting disease patterns in psoriasis and atopic dermatitis,” Archives of Dermatological Research, vol. 279, no. 1, pp. S48–S51, 1987. View at: Publisher Site | Google Scholar
  8. E. Guttman-Yassky and J. G. Krueger, “Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?” Current Opinion in Immunology, vol. 48, pp. 68–73, 2017. View at: Publisher Site | Google Scholar
  9. E. Suzuki, E. D. Mellins, M. E. Gershwin, F. O. Nestle, and I. E. Adamopoulos, “The IL-23/IL-17 axis in psoriatic arthritis,” Autoimmunity Reviews, vol. 13, no. 4-5, pp. 496–502, 2014. View at: Publisher Site | Google Scholar
  10. J. S. Cunha, A. A. Qureshi, and A. M. Reginato, “Nail enthesis ultrasound in psoriasis and psoriatic arthritis: a report from the 2016 GRAPPA annual meeting,” The Journal of Rheumatology, vol. 44, no. 5, pp. 688–690, 2017. View at: Publisher Site | Google Scholar
  11. E. Hajdarbegovic, A. Westgeest, and H. B. Thio, “Atopy in cutaneous and arthropatic psoriasis,” Journal of Translational Medicine, vol. 8, no. Suppl 1, p. 15, 2010. View at: Publisher Site | Google Scholar
  12. M. Nakamura, K. Lee, R. Singh et al., “Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review,” Journal of Dermatological Treatment, vol. 28, no. 3, pp. 237–241, 2017. View at: Publisher Site | Google Scholar
  13. M. Megna et al., “Systemic treatment of adult atopic dermatitis: a review,” Dermatology and Therapy, vol. 7, no. 1, 2017. View at: Google Scholar

Copyright © 2018 Gerhard Eichhoff and Noriko Soffi Harun. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views1590
Downloads410
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.